FAQ: Cybin Inc.'s Participation in Cantor Global Healthcare Conference and Company Overview

What is the main announcement in this content?

Cybin Inc. announced that Chief Medical Officer Amir Inamdar will participate in a fireside chat at the Cantor Global Healthcare Conference scheduled for September 3-5, 2025. The session will be webcast live on Friday, September 5 at 10:20 a.m. ET.

Who is participating from Cybin and what is their role?

Amir Inamdar, Cybin’s Chief Medical Officer, will be participating in the fireside chat. He represents the clinical-stage neuropsychiatry company that develops next-generation treatment options for mental healthcare.

When and where will the conference session take place?

The Cantor Global Healthcare Conference is scheduled for September 3-5, 2025, with Cybin’s fireside chat session occurring on Friday, September 5 at 10:20 a.m. ET. The session will be webcast live with an archived replay available on Cybin’s investor relations website.

What is Cybin Inc. and what does the company do?

Cybin is a clinical-stage neuropsychiatry company developing next-generation treatment options for mental healthcare. The company is committed to revolutionizing mental healthcare by developing new and innovative treatments to address unmet needs for people suffering from mental health conditions.

What specific treatments is Cybin currently developing?

Cybin is developing CYB003, a proprietary deuterated psilocin analog in Phase 3 studies for adjunctive treatment of major depressive disorder, and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The company also has a research pipeline of investigational, 5-HT-receptor focused compounds.

Where is Cybin operational and when was it founded?

Cybin was founded in 2019 and is operational in Canada, the United States, the United Kingdom, and Ireland. The company has international presence supporting its clinical-stage neuropsychiatry development programs.

How can investors access the full press release and stay updated on Cybin news?

The full press release can be viewed at https://ibn.fm/N8ObB. The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN.

What regulatory milestone has Cybin achieved for its CYB003 treatment?

CYB003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. This designation is for the adjunctive treatment of major depressive disorder and indicates the treatment’s potential to address unmet medical needs.

Why is this conference participation significant for investors and stakeholders?

This conference participation provides investors and stakeholders with direct access to Cybin’s clinical leadership and updates on the company’s progress. The webcast availability ensures broad accessibility to information about Cybin’s next-generation mental health treatments and development pipeline.